Dupilumab Treatment Leads to Sustained Reductions in Oral Corticosteroid Use in Patients With Oral Corticosteroid–Dependent Severe Asthma

Mark Gurnell; Christian  Domingo; Klaus F Rabe; Andrew Menzies-Gow; David Price; Guy  Brusselle; Michael E Wechsler; Changming  Xia; Nami  Pandit-Abid; Rebecca Gall; Juby A.  Jacob-Nara; Paul J.  Rowe; Yamo  Deniz; Shahid  Siddiqui

Dupilumab Treatment Leads to Sustained Reductions in Oral Corticosteroid Use in Patients With Oral Corticosteroid–Dependent Severe Asthma

Mark Gurnell, Christian Domingo, Klaus F Rabe, Andrew Menzies-Gow, David Price, Guy Brusselle, Michael E Wechsler, Changming Xia, Nami Pandit-Abid, Rebecca Gall, Juby A. Jacob-Nara, Paul J. Rowe, Yamo Deniz, Shahid Siddiqui

Research output: Contribution to conference › Abstract › peer-review

Original language	English
Publication status	Accepted/In press - 2 Aug 2022
Event	CHEST 2022 - Music City Center , Nashville , United States Duration: 16 Oct 2022 → 19 Oct 2022 https://www.chestnet.org/Learning-and-Events/Events/CHEST-Annual-Meeting

Conference

Conference	CHEST 2022
Country/Territory	United States
City	Nashville
Period	16/10/22 → 19/10/22
Internet address	https://www.chestnet.org/Learning-and-Events/Events/CHEST-Annual-Meeting

Bibliographical note

Acknowledgments and funding sources
Research sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. ClinicalTrials.gov Identifiers: NCT02528214 (VENTURE)/NCT02134028 (TRAVERSE). Medical writing/editorial assistance was provided by Éilis Sutton, PhD, of Excerpta Medica, and was funded by Sanofi and Regeneron Pharmaceuticals, Inc., according to the Good Publication Practice guideline.

Cite this

Gurnell, M., Domingo, C., Rabe, K. F., Menzies-Gow, A., Price, D., Brusselle, G., Wechsler, M. E., Xia, C., Pandit-Abid, N., Gall, R., Jacob-Nara, J. A., Rowe, P. J., Deniz, Y., & Siddiqui, S. (Accepted/In press). Dupilumab Treatment Leads to Sustained Reductions in Oral Corticosteroid Use in Patients With Oral Corticosteroid–Dependent Severe Asthma. Abstract from CHEST 2022, Nashville , Tennessee, United States.

Gurnell, M, Domingo, C, Rabe, KF, Menzies-Gow, A, Price, D, Brusselle, G, Wechsler, ME, Xia, C, Pandit-Abid, N, Gall, R, Jacob-Nara, JA, Rowe, PJ, Deniz, Y & Siddiqui, S 2022, 'Dupilumab Treatment Leads to Sustained Reductions in Oral Corticosteroid Use in Patients With Oral Corticosteroid–Dependent Severe Asthma', CHEST 2022, Nashville , United States, 16/10/22 - 19/10/22.

@conference{bd68dc4379034f08b6fecddc5f0ffbde,

title = "Dupilumab Treatment Leads to Sustained Reductions in Oral Corticosteroid Use in Patients With Oral Corticosteroid–Dependent Severe Asthma",

author = "Mark Gurnell and Christian Domingo and Rabe, {Klaus F} and Andrew Menzies-Gow and David Price and Guy Brusselle and Wechsler, {Michael E} and Changming Xia and Nami Pandit-Abid and Rebecca Gall and Jacob-Nara, {Juby A.} and Rowe, {Paul J.} and Yamo Deniz and Shahid Siddiqui",

note = "Acknowledgments and funding sources Research sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. ClinicalTrials.gov Identifiers: NCT02528214 (VENTURE)/NCT02134028 (TRAVERSE). Medical writing/editorial assistance was provided by {\'E}ilis Sutton, PhD, of Excerpta Medica, and was funded by Sanofi and Regeneron Pharmaceuticals, Inc., according to the Good Publication Practice guideline.; CHEST 2022 ; Conference date: 16-10-2022 Through 19-10-2022",

year = "2022",

month = aug,

day = "2",

language = "English",

url = "https://www.chestnet.org/Learning-and-Events/Events/CHEST-Annual-Meeting",

}

TY - CONF

T1 - Dupilumab Treatment Leads to Sustained Reductions in Oral Corticosteroid Use in Patients With Oral Corticosteroid–Dependent Severe Asthma

AU - Gurnell, Mark

AU - Domingo, Christian

AU - Rabe, Klaus F

AU - Menzies-Gow, Andrew

AU - Price, David

AU - Brusselle, Guy

AU - Wechsler, Michael E

AU - Xia, Changming

AU - Pandit-Abid, Nami

AU - Gall, Rebecca

AU - Jacob-Nara, Juby A.

AU - Rowe, Paul J.

AU - Deniz, Yamo

AU - Siddiqui, Shahid

N1 - Acknowledgments and funding sources Research sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. ClinicalTrials.gov Identifiers: NCT02528214 (VENTURE)/NCT02134028 (TRAVERSE). Medical writing/editorial assistance was provided by Éilis Sutton, PhD, of Excerpta Medica, and was funded by Sanofi and Regeneron Pharmaceuticals, Inc., according to the Good Publication Practice guideline.

PY - 2022/8/2

Y1 - 2022/8/2

M3 - Abstract

T2 - CHEST 2022

Y2 - 16 October 2022 through 19 October 2022

ER -